Travere Therapeutics (TVTX) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$52.12
+0.2% on the day
+99.9% over 12 months
52-week range $25.16 – $67.52
Share price and insider trades
TVTX closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$104M
Insiders buying0
Insiders selling11
Travere Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 11 sold $104M of TVTX stock on the open market.
Get emailed when insiders cluster-buy stocks like TVTX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
TVTX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $67.0M | 46 |
| Q2 2026 | — | 0 | $16.5M | 40 |
| Q1 2026 | — | 0 | $9.5M | 23 |
| Q4 2025 | — | 0 | $11.3M | 12 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.5×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Travere Therapeutics, Inc. insiders reported open-market purchases totaling $0, while 11 insiders reported sales totaling $104M. 113 of 121 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 17SEC | Eric M DubeCEO | Sell Plan | 101,691439,688 held (−19%) | $64.59 | $6.6M | -19.3% | — |
| Sep 17SEC | Eric M DubeCEO | Sell Plan | 99,716529,011 held (−16%) | $63.26 | $6.3M | -17.6% | — |
| Sep 17SEC | Eric M DubeCEO | Sell Plan | 96,125432,886 held (−18%) | $63.64 | $6.1M | -18.1% | — |
| Sep 17SEC | Peter HeermaEvp, Chief Commercial Officer | Sell Plan | 93,604196,179 held (−32%) | $63.25 | $5.9M | -17.6% | — |
| Sep 17SEC | Peter HeermaEvp, Chief Commercial Officer | Sell Plan | 79,113117,066 held (−40%) | $63.65 | $5.0M | -18.1% | — |
| Sep 17SEC | Peter HeermaEvp, Chief Commercial Officer | Sell Plan | 71,938147,318 held (−33%) | $62.05 | $4.5M | -16.0% | — |
| Sep 17SEC | William E. RoteChief Research Officer | Sell Plan | 65,104145,943 held (−31%) | $63.12 | $4.1M | -17.4% | — |
| Sep 17SEC | William E. RoteChief Research Officer | Sell Plan | 63,907130,488 held (−33%) | $61.99 | $4.0M | -15.9% | — |
| Sep 17SEC | Eric M DubeCEO | Sell Plan | 63,498465,054 held (−12%) | $61.99 | $3.9M | -15.9% | — |
| Sep 17SEC | William E. RoteChief Research Officer | Sell Plan | 47,74698,197 held (−33%) | $63.61 | $3.0M | -18.1% | — |
| Sep 17SEC | William E. RoteChief Research Officer | Sell Plan | 29,021101,467 held (−22%) | $62.66 | $1.8M | -16.8% | — |
| Sep 17SEC | Eric M DubeCEO | Sell Plan | 28,796436,258 held (−6%) | $62.66 | $1.8M | -16.8% | — |
| Sep 17SEC | Peter HeermaEvp, Chief Commercial Officer | Sell Plan | 27,421119,897 held (−19%) | $62.59 | $1.7M | -16.7% | — |
| Sep 17SEC | Christopher R. ClineCFO | Sell Plan | 27,473110,543 held (−20%) | $62.00 | $1.7M | -15.9% | — |
| Sep 17SEC | Jula InrigEvp, Head Of R&D & Cmo | Sell Plan | 25,390119,775 held (−17%) | $62.02 | $1.6M | -16.0% | — |
| Sep 17SEC | Elizabeth E ReedGeneral Counsel | Sell Plan | 21,926120,963 held (−15%) | $62.03 | $1.4M | -16.0% | — |
| Sep 17SEC | Christopher R. ClineCFO | Sell Plan | 20,73589,808 held (−19%) | $62.61 | $1.3M | -16.7% | — |
| Sep 17SEC | Jula InrigEvp, Head Of R&D & Cmo | Sell Plan | 17,284102,491 held (−14%) | $62.62 | $1.1M | -16.8% | — |
| Sep 17SEC | Elizabeth E ReedGeneral Counsel | Sell Plan | 13,874107,089 held (−11%) | $62.63 | $869K | -16.8% | — |
| Sep 17SEC | Peter HeermaEvp, Chief Commercial Officer | Sell Plan | 8,282117,066 held (−7%) | $65.07 | $539K | -19.9% | — |
| Sep 17SEC | Eric M DubeCEO | Sell Plan | 6,802432,886 held (−2%) | $64.95 | $442K | -19.7% | — |
| Sep 17SEC | Sandra CalvinSvp, Chief Accounting Officer | Sell Plan | 4,27543,453 held (−9%) | $62.14 | $266K | -16.1% | — |
| Sep 17SEC | Eric M DubeCEO | Sell Plan | 3,102433,156 held (−1%) | $63.64 | $197K | -18.1% | — |
| Sep 17SEC | William E. RoteChief Research Officer | Sell Plan | 3,00098,467 held (−3%) | $63.65 | $191K | -18.1% | — |
| Sep 17SEC | Christopher R. ClineCFO | Sell Plan | 1,90087,908 held (−2%) | $63.69 | $121K | -18.2% | — |
| Sep 17SEC | Jula InrigEvp, Head Of R&D & Cmo | Sell Plan | 1,600100,891 held (−2%) | $63.69 | $102K | -18.2% | — |
| Sep 17SEC | Peter HeermaEvp, Chief Commercial Officer | Sell Plan | 1,431117,066 held (−1%) | $65.31 | $93K | -20.2% | — |
| Sep 17SEC | Elizabeth E ReedGeneral Counsel | Sell Plan | 1,400105,689 held (−1%) | $63.69 | $89K | -18.2% | — |
| Sep 17SEC | Peter HeermaEvp, Chief Commercial Officer | Sell Plan | 1,400118,497 held (−1%) | $63.65 | $89K | -18.1% | — |
| Sep 17SEC | Sandra CalvinSvp, Chief Accounting Officer | Sell Plan | 80042,653 held (−2%) | $62.85 | $50K | -17.1% | — |
| Sep 17SEC | Jula InrigEvp, Head Of R&D & Cmo | Sell Plan | 400100,491 held (−0%) | $65.31 | $26K | -20.2% | — |
| Sep 17SEC | Christopher R. ClineCFO | Sell Plan | 40087,508 held (−0%) | $65.31 | $26K | -20.2% | — |
| Sep 17SEC | Elizabeth E ReedGeneral Counsel | Sell Plan | 300105,389 held (−0%) | $65.31 | $20K | -20.2% | — |
| Sep 17SEC | Sandra CalvinSvp, Chief Accounting Officer | Sell Plan | 30042,353 held (−1%) | $63.66 | $19K | -18.1% | — |
| Sep 17SEC | Eric M DubeCEO | Sell Plan | 270432,886 held (−0%) | $65.31 | $18K | -20.2% | — |
| Sep 17SEC | William E. RoteChief Research Officer | Sell Plan | 27098,197 held (−0%) | $65.31 | $18K | -20.2% | — |
| Sep 11SEC | Jeffrey A MecklerDirector | Sell Plan | 14,00094,600 held (−13%) | $67.46 | $944K | -22.7% | — |
| Sep 11SEC | Jeffrey A MecklerDirector | Sell Plan | 3,10091,500 held (−3%) | $68.09 | $211K | -23.4% | — |
| Sep 11SEC | Jeffrey A MecklerDirector | Sell Plan | 1,700109,800 held (−2%) | $65.39 | $111K | -20.3% | — |
| Sep 11SEC | Jeffrey A MecklerDirector | Sell Plan | 1,200108,600 held (−1%) | $66.15 | $79K | -21.2% | — |
| Sep 3SEC | Christopher R. ClineCFO | Sell | 642118,016 held (−1%) | $66.37 | $43K | -21.5% | — |
| Aug 19SEC | Gary A LyonsDirector | Sell Plan | 4,10062,400 held (−6%) | $63.27 | $259K | -17.6% | — |
| Aug 19SEC | Gary A LyonsDirector | Sell Plan | 2,60062,000 held (−4%) | $63.50 | $165K | -17.9% | — |
| Aug 19SEC | Gary A LyonsDirector | Sell Plan | 1,90064,600 held (−3%) | $62.53 | $119K | -16.6% | — |
| Aug 19SEC | Gary A LyonsDirector | Sell Plan | 90061,500 held (−1%) | $63.86 | $57K | -18.4% | — |
| Aug 19SEC | Gary A LyonsDirector | Sell Plan | 50061,500 held (−1%) | $64.16 | $32K | -18.8% | — |
| Jun 16SEC | Timothy CoughlinDirector | Sell Plan | 10,00056,250 held (−15%) | $50.07 | $501K | +4.1% | — |
| Jun 16SEC | Roy D. BaynesDirector | Sell Plan | 4,50041,500 held (−10%) | $50.00 | $225K | +4.2% | — |
| May 19SEC | Timothy CoughlinDirector | Sell Plan | 3,25052,250 held (−6%) | $43.49 | $141K | +19.9% | — |
| May 6SEC | Eric M DubeCEO | Sell Plan | 22,500432,886 held (−5%) | $43.95 | $989K | +18.6% | — |
| May 6SEC | Elizabeth E ReedGeneral Counsel | Sell Plan | 20,000105,211 held (−16%) | $45.00 | $900K | +15.8% | — |
| May 6SEC | Jula InrigChief Medical Officer | Sell Plan | 20,000111,473 held (−15%) | $45.00 | $900K | +15.8% | — |
| May 6SEC | Jeffrey A MecklerDirector | Sell Plan | 8,00087,500 held (−8%) | $45.00 | $360K | +15.8% | — |
| May 6SEC | Roy D. BaynesDirector | Sell Plan | 4,50037,500 held (−11%) | $46.65 | $210K | +11.7% | — |
| May 6SEC | William E. RoteChief Research Officer | Sell Plan | 2,763115,474 held (−2%) | $43.95 | $121K | +18.6% | — |
| May 6SEC | Christopher R. ClineCFO | Sell Plan | 2,181118,968 held (−2%) | $46.65 | $102K | +11.7% | — |
| May 6SEC | Peter HeermaChief Commercial Officer | Sell | 2,174140,684 held (−2%) | $46.65 | $101K | +11.7% | — |
| May 6SEC | Elizabeth E ReedGeneral Counsel | Sell Plan | 2,174107,287 held (−2%) | $46.65 | $101K | +11.7% | — |
| May 6SEC | Jula InrigChief Medical Officer | Sell Plan | 2,174113,549 held (−2%) | $46.65 | $101K | +11.7% | — |
| May 6SEC | Elizabeth E ReedGeneral Counsel | Sell Plan | 2,076105,211 held (−2%) | $43.95 | $91K | +18.6% | — |
| May 6SEC | Jula InrigChief Medical Officer | Sell Plan | 311113,238 held (−0%) | $43.95 | $14K | +18.6% | — |
| May 6SEC | Christopher R. ClineCFO | Sell Plan | 310118,658 held (−0%) | $43.95 | $14K | +18.6% | — |
| May 4SEC | Roy D. BaynesDirector | Sell Plan | 9,75037,500 held (−21%) | $44.22 | $431K | +17.9% | — |
| Apr 23SEC | William E. RoteChief Research Officer | Sell Plan | 9,100113,987 held (−7%) | $39.09 | $356K | +33.3% | — |
| Apr 16SEC | Roy D. BaynesDirector | Sell Plan | 26,00044,250 held (−37%) | $41.07 | $1.1M | +26.9% | — |
| Apr 16SEC | Sandra CalvinSvp, Chief Accounting Officer | Sell Plan | 21,97742,353 held (−34%) | $41.07 | $903K | +26.9% | — |
| Apr 16SEC | Gary A LyonsDirector | Sell Plan | 8,00057,500 held (−12%) | $41.07 | $329K | +26.9% | — |
| Apr 16SEC | Roy D. BaynesDirector | Sell Plan | 6,75037,500 held (−15%) | $42.12 | $284K | +23.8% | — |
| Apr 15SEC | Eric M DubeCEO | Sell Plan | 56,815440,071 held (−11%) | $41.01 | $2.3M | +27.1% | — |
| Apr 15SEC | Elizabeth E ReedGeneral Counsel | Sell Plan | 37,500119,211 held (−24%) | $41.07 | $1.5M | +26.9% | — |
| Apr 15SEC | Christopher R. ClineCFO | Sell Plan | 7,239117,913 held (−6%) | $41.93 | $304K | +24.3% | — |
| Apr 15SEC | Peter HeermaChief Commercial Officer | Sell | 7,215138,608 held (−5%) | $41.93 | $303K | +24.3% | — |
| Apr 15SEC | Jula InrigChief Medical Officer | Sell Plan | 7,215112,491 held (−6%) | $41.93 | $303K | +24.3% | — |
| Apr 15SEC | Elizabeth E ReedGeneral Counsel | Sell Plan | 7,215111,996 held (−6%) | $41.93 | $303K | +24.3% | — |
| Apr 15SEC | Eric M DubeCEO | Sell Plan | 7,165432,906 held (−2%) | $41.75 | $299K | +24.9% | — |
| Apr 15SEC | Elizabeth E ReedGeneral Counsel | Sell Plan | 5,226106,770 held (−5%) | $41.62 | $218K | +25.2% | — |
| Apr 15SEC | Elizabeth E ReedGeneral Counsel | Sell Plan | 1,559105,211 held (−1%) | $42.53 | $66K | +22.6% | — |
| Apr 15SEC | Jula InrigChief Medical Officer | Sell Plan | 1,018111,473 held (−1%) | $42.61 | $43K | +22.3% | — |
| Apr 15SEC | Christopher R. ClineCFO | Sell Plan | 1,014116,899 held (−1%) | $42.61 | $43K | +22.3% | — |
| Apr 15SEC | Christopher R. ClineCFO | Sell Plan | 65125,161 held (−0%) | $28.85 | $2K | +80.7% | — |
| Apr 15SEC | Eric M DubeCEO | Sell Plan | 20432,886 held (−0%) | $42.66 | $853 | +22.2% | — |
| Apr 15SEC | Christopher R. ClineCFO | Sell Plan | 9125,152 held (−0%) | $41.07 | $370 | +26.9% | — |
| Apr 7SEC | Roy D. BaynesDirector | Sell Plan | 10,00037,500 held (−21%) | $33.00 | $330K | +58.0% | — |
| Apr 2SEC | Eric M DubeCEO | Sell Plan | 34,902457,984 held (−7%) | $30.55 | $1.1M | +70.6% | — |
| Apr 2SEC | Eric M DubeCEO | Sell Plan | 25,098432,886 held (−5%) | $31.46 | $790K | +65.7% | — |
| Apr 2SEC | Elizabeth E ReedGeneral Counsel | Sell Plan | 10,000105,211 held (−9%) | $30.00 | $300K | +73.8% | — |
| Mar 18SEC | Elizabeth E ReedGeneral Counsel | Sell Plan | 10,000105,211 held (−9%) | $28.09 | $281K | +85.6% | — |
| Feb 24SEC | Eric M DubeCEO | Sell Plan | 60,000432,886 held (−12%) | $30.10 | $1.8M | +73.2% | — |
| Feb 19SEC | Elizabeth E ReedGeneral Counsel | Sell Plan | 5,679109,532 held (−5%) | $27.50 | $156K | +89.5% | — |
| Feb 19SEC | Elizabeth E ReedGeneral Counsel | Sell Plan | 4,321105,211 held (−4%) | $28.26 | $122K | +84.4% | — |
| Feb 5SEC | Elizabeth E ReedGeneral Counsel | Sell Plan | 2,485105,720 held (−2%) | $32.07 | $80K | +62.5% | — |
| Feb 5SEC | Christopher R. ClineCFO | Sell Plan | 1,635111,336 held (−1%) | $32.14 | $53K | +62.2% | — |
| Feb 5SEC | Jula InrigChief Medical Officer | Sell Plan | 1,547105,938 held (−1%) | $32.11 | $50K | +62.3% | — |
| Feb 5SEC | Elizabeth E ReedGeneral Counsel | Sell Plan | 509105,211 held (−0%) | $32.74 | $17K | +59.2% | — |
| Feb 5SEC | Jula InrigChief Medical Officer | Sell Plan | 232105,706 held (−0%) | $32.85 | $8K | +58.7% | — |
| Feb 5SEC | Christopher R. ClineCFO | Sell Plan | 110111,226 held (−0%) | $32.90 | $4K | +58.4% | — |
| Feb 3SEC | Eric M DubeCEO | Sell Plan | 66,452466,521 held (−12%) | $32.06 | $2.1M | +62.6% | — |
| Feb 3SEC | Eric M DubeCEO | Sell Plan | 33,635432,886 held (−7%) | $32.70 | $1.1M | +59.4% | — |
| Feb 3SEC | William E. RoteChief Research Officer | Sell Plan | 12,446109,087 held (−10%) | $32.87 | $409K | +58.6% | — |
| Feb 3SEC | Peter HeermaChief Commercial Officer | Sell | 7,310131,823 held (−5%) | $32.12 | $235K | +62.3% | — |
| Feb 3SEC | Christopher R. ClineCFO | Sell | 7,242112,971 held (−6%) | $32.12 | $233K | +62.3% | — |
| Feb 3SEC | Elizabeth E ReedGeneral Counsel | Sell | 7,175108,205 held (−6%) | $32.12 | $230K | +62.3% | — |
| Feb 3SEC | Jula InrigChief Medical Officer | Sell | 6,956107,485 held (−6%) | $32.12 | $223K | +62.3% | — |
| Feb 3SEC | Sandra CalvinSvp, Chief Accounting Officer | Sell | 4,33349,080 held (−8%) | $32.12 | $139K | +62.3% | — |
| Jan 27SEC | Eric M DubeCEO | Sell Plan | 51,865419,173 held (−11%) | $30.10 | $1.6M | +73.2% | — |
| Jan 27SEC | Eric M DubeCEO | Sell Plan | 8,135419,173 held (−2%) | $30.01 | $244K | +73.7% | — |
| Jan 21SEC | Elizabeth E ReedGeneral Counsel | Sell Plan | 10,00090,270 held (−10%) | $27.34 | $273K | +90.7% | — |
| Jan 7SEC | Jula InrigChief Medical Officer | Sell Plan | 2,03186,756 held (−2%) | $40.18 | $82K | +29.7% | — |
| Jan 7SEC | Jula InrigChief Medical Officer | Sell Plan | 44586,311 held (−1%) | $37.75 | $17K | +38.1% | — |
| Dec 29SEC | William E. RoteChief Research Officer | Sell Plan | 60,000101,443 held (−37%) | $40.10 | $2.4M | +30.0% | — |
| Dec 29SEC | Jula InrigChief Medical Officer | Sell Plan | 15,00088,787 held (−14%) | $42.00 | $630K | +24.1% | — |
| Dec 29SEC | Sandra CalvinSvp, Chief Accounting Officer | Sell Plan | 7,40238,233 held (−16%) | $40.00 | $296K | +30.3% | — |
| Dec 29SEC | Peter HeermaChief Commercial Officer | Sell Plan | 4,980113,013 held (−4%) | $40.00 | $199K | +30.3% | — |
| Dec 16SEC | Sandra CalvinSvp, Chief Accounting Officer | Sell Plan | 2,91045,635 held (−6%) | $36.00 | $105K | +44.8% | — |
| Dec 3SEC | Christopher R. ClineCFO | Sell Plan | 20,00092,083 held (−18%) | $35.01 | $700K | +48.9% | — |
| Nov 6SEC | Sandra CalvinSvp, Chief Accounting Officer | Sell Plan | 67,11548,545 held (−58%) | $36.00 | $2.4M | +44.8% | — |
| Nov 4SEC | Timothy CoughlinDirector | Sell Plan | 18,00055,500 held (−24%) | $35.03 | $631K | +48.8% | — |
| Nov 4SEC | Peter HeermaChief Commercial Officer | Sell Plan | 5,591119,071 held (−4%) | $35.00 | $196K | +48.9% | — |
| Oct 30SEC | Eric M DubeCEO | Sell Plan | 92,872419,173 held (−18%) | $30.38 | $2.8M | +71.6% | — |
| Oct 30SEC | Eric M DubeCEO | Sell Plan | 27,128419,173 held (−6%) | $30.12 | $817K | +73.1% | — |
| Oct 30SEC | Peter HeermaChief Commercial Officer | Sell Plan | 2,662124,662 held (−2%) | $30.00 | $80K | +73.8% | — |
Insiders at Travere Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Eric M DubeCEO | — | $41.3M | Sep 17, 2026 | — |
| Peter HeermaEvp, Chief Commercial Officer | — | $19.0M | Sep 17, 2026 | — |
| William E. RoteChief Research Officer | — | $16.4M | Sep 17, 2026 | — |
| Elizabeth E ReedGeneral Counsel | — | $7.0M | Sep 17, 2026 | — |
| Jula InrigEvp, Head Of R&D & Cmo | — | $5.2M | Sep 17, 2026 | — |
| Christopher R. ClineCFO | — | $4.6M | Sep 17, 2026 | — |
| Sandra CalvinSvp, Chief Accounting Officer | — | $4.2M | Sep 17, 2026 | — |
| Roy D. BaynesDirector | — | $2.5M | Jun 16, 2026 | — |
| Jeffrey A MecklerDirector | — | $1.7M | Sep 11, 2026 | — |
| Timothy CoughlinDirector | — | $1.3M | Jun 16, 2026 | — |
| Gary A LyonsDirector | — | $961K | Aug 19, 2026 | — |
TVTX stock: common questions
Are Travere Therapeutics, Inc. insiders buying TVTX stock?
In the past 12 months, 0 insiders reported open-market purchases of TVTX worth $0.
Are Travere Therapeutics, Inc. insiders selling TVTX stock?
11 insiders reported sales worth $104M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is TVTX's 52-week range?
Over the past year TVTX has traded between $25.16 and $67.52. It last closed at $52.12 on Oct 9, 2026.